Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 6/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 5/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.33 |
| ▸ | CDK2 | P24941 | 5/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.33 |
| ▸ | CDK9 | P50750 | 3/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10399879 | 0.98 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| Bromide SCHEMBL7381858 | 0.98 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| Bromide SCHEMBL7381867 | 0.98 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4053018 | 0.88 | DYRK1A (0.41) | KDM4EALDH1A1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL23748001 | 0.82 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12798307 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL477062 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13122629 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31001942 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22330380 | 0.75 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4609731-A | Process for brominating ergot alkaloids | SANDOZ LTD. (CH) | 1986-09-02 | — | — | US | claimed |
| US-20240124469-A1 | PIM KINASE INHIBITOR | HANGZHOU BIOSUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4289847-A1 | PIM KINASE INHIBITOR | Hangzhou Biosun Pharmaceutical Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-115991706-A | PIM kinase inhibitors | 杭州邦顺制药有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-114409656-B | PIM kinase inhibitors | 杭州邦顺制药有限公司 | 2022-09-23 | — | — | CN | disclosed |
| WO-2022166860-A1 | PIM KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| CN-114409656-A | PIM kinase inhibitors | 杭州邦顺制药有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| EP-2079744-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| EP-1972631-A1 | Imidazopyridazines as PI3K lipid kinase inhibitors | Novartis AG (CH) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008052733-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| EP-0118848-B1 | ERGOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL APPLICATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-02-19 | — | — | EP | disclosed |
| US-4853390-A | NEUROLEPTIC AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-08-01 | — | — | US | disclosed |
| US-4766128-A | Optionally 11- to 13-substituted ergoline compounds useful as medicinal agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-08-23 | — | — | US | disclosed |
| EP-0056358-B1 | NOVEL (2-HALOERGOLINYL)-N'-N'-DIETHYLUREA DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND USE THEREOF AS MEDICINAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-04-22 | — | — | EP | disclosed |
| US-4609731-A | Process for brominating ergot alkaloids | SANDOZ LTD. (CH) | 1986-09-02 | — | — | US | disclosed |
| US-4609731-A | Process for brominating ergot alkaloids | SANDOZ LTD. (CH) | 1986-09-02 | — | — | US | disclosed |
| EP-0056358-A1 | Novel (2-haloergolinyl)-N'-N'-diethylurea derivatives, process for the preparation thereof, and use thereof as medicinal agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | KDM4E 885/4885ALDH1A1 3770/4885SMN1; SMN2 2679/4885 |
| US-20240124469-A1 | PIM KINASE INHIBITOR | PIM1, PIM2, PIM3 | KDM4E 609/4885ALDH1A1 1562/4885SMN1; SMN2 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.